2020ASCO high-profile domestic and international PD-1/PD-L1 with the same competition

PD-1/PD-L1 immunotherapy, which has attracted worldwide attention, is revolutionizing cancer treatmentTo date, a total of 10 PD-1/PD-L1 inhibitors have been approved for market, including a total of 8 domestic lying, including 4 domestic PD-1 inhibitors, 2 imported PD-1 inhibitors and 2 imported PD-L1 inhibitors, lung cancer, stomach cancer, liver cancer is the focus of imported PD-1/PD-L1 indication development, while the four domestic PD-1 inhibitors are through the less common domestic indications, such as melanoma, Hodgkin lymphoma, as its way to quickly enter the marketTable 1 PD-1/PD-L1 Inhibitors Global Research Progressdata source: FDA, EMA Pipe Network, Insight Databaseas the Olympic Games of the Anticancer Community ASCO will be officially launched online on May 29, 2020Now that some of the hard-weight research findings and clinical data results have been released in summary form, let's take a look at the latest developments in international PD-1/PD-L1Table 2 International PD-1/PD-L1 Heavy Clinical Results PublishedData Source: ASCO official website, only finishing Phase III Clinical Report
domestic pharmaceutical companies follow the international pace, accelerate the process of clinical development and marketing of PD-1/PD-L1, take stock of this ASCO, domestic PD-1/PD-L1 clinical data also attracted worldwide attention!Table 3 Domestic PD-1/PD-L1 Clinical Results PublishedoutlookPD-1/PD-L1 antibody good efficacy, broad market space, attracting a large number of pharmaceutical companies to invest heavilyWith the gradual standardization of tumor combination therapy, the model of "immunotherapy plus" is becoming more and more clear, becoming the direction of future tumor treatmentAlthough domestic enterprises in the progress of research and development behind the foreign pharmaceutical giants, but also has been closely following the trend of international research and development, coupled with the support of national policies, I believe that domestic patients will soon usher in the domestic PD-1/PD-L1 listing boomfollowed by International PD-1/PD-L1 Variety 2 and the following reports:clinical phase II PD-L1 developed by Research Variety (1) CytomX Therapeutics Inc.; (2) Janssen Research Development and LLC Developed Clinical Phase II PD1 (Summary No 3055); (3) INC MGA00012 (summary number TPS4662), currently owned by Reeding Pharmaceuticals and Incyte Corp, presenting a Phase II solution; Table 4 Clinical Phase 2 and below, led by the original research party, can pay its own attention as needed
In addition, the listed varieties also have the following 2 drugs 3 clinical studies, due to the limited length of the table, listed separately: (1) 10018-phase II cemiplimab Single drug treatment of advanced skin squamous cell carcinoma; (2) LBA6008-Phase II Avelumab compared to single chemotherapy: pregnancy nourishing cell tumors; (3) 10521-Phase II Avelumab treats adolescent patients with recurrent or sexual osteosarcoma.